Drug intelligence / Profile preview

UI009

Development stage: Phase 1
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Inhalation

Overview

UI009 is an inhaled pharmaceutical drug developed by Korea United Pharm, currently in Phase 1 trials. It is indicated for respiratory diseases. Available clinical trial data indicate it is being compared for bioequivalence with UIC202005, with measurement of fluticasone propionate plasma concentrations suggesting that UI009 contains fluticasone propionate as its active ingredient[1][6]. Fluticasone propionate is a synthetic glucocorticoid used in the treatment of asthma and other respiratory diseases via activation of the glucocorticoid receptor, which suppresses airway inflammation and eosinophilia[2].

Brand names: UI009UI-009UI 009
Other names: UI009UI-009UI 009

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on UI009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI009.

Explore the full profile